Wedbush Research Analysts Boost Earnings Estimates for APGE

Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Analysts at Wedbush increased their Q2 2025 earnings per share estimates for shares of Apogee Therapeutics in a note issued to investors on Monday, May 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.03) per share for the quarter, up from their prior forecast of ($1.26). Wedbush has a "Outperform" rating and a $90.00 price objective on the stock. The consensus estimate for Apogee Therapeutics' current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics' Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.89) EPS, FY2026 earnings at ($4.07) EPS, FY2027 earnings at ($4.50) EPS, FY2028 earnings at ($5.47) EPS and FY2029 earnings at ($5.03) EPS.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24.

Other analysts also recently issued research reports about the company. Citigroup assumed coverage on Apogee Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $95.00 price target for the company. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $94.60.

Apogee Therapeutics Trading Up 0.4%

Shares of APGE opened at $39.74 on Wednesday. The company has a market cap of $1.78 billion, a PE ratio of -16.42 and a beta of 1.70. The stock has a 50-day moving average price of $36.51 and a 200-day moving average price of $41.41. Apogee Therapeutics has a 12-month low of $26.20 and a 12-month high of $63.50.

Institutional Trading of Apogee Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of APGE. Mercer Global Advisors Inc. ADV bought a new stake in Apogee Therapeutics in the fourth quarter valued at approximately $32,621,000. Janus Henderson Group PLC lifted its position in Apogee Therapeutics by 141.7% in the fourth quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company's stock valued at $51,455,000 after purchasing an additional 665,543 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its position in Apogee Therapeutics by 82.9% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company's stock valued at $58,155,000 after purchasing an additional 581,949 shares during the last quarter. Jefferies Financial Group Inc. lifted its position in Apogee Therapeutics by 140.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 887,497 shares of the company's stock valued at $40,204,000 after purchasing an additional 518,300 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Apogee Therapeutics by 38.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company's stock valued at $47,683,000 after purchasing an additional 294,514 shares during the last quarter. Institutional investors own 79.04% of the company's stock.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 2,725 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $35.75, for a total value of $97,418.75. Following the completion of the sale, the insider now owns 244,448 shares in the company, valued at $8,739,016. The trade was a 1.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at $38,983,558.05. The trade was a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,175 shares of company stock worth $587,191 in the last quarter. 36.10% of the stock is owned by insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.